Prosecution Insights
Last updated: November 12, 2026
Application No. 18/835,559

METHODS OF WEIGHT LOSS AND PRESERVING SKELETAL MUSCLE MASS

Non-Final OA §102§103§112§DOUBLEPATENT
Filed
Aug 02, 2024
Priority
Feb 07, 2022 — provisional 63/307,506 +2 more
Examiner
NOTTINGHAM, KYLE GREGORY
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Rivus Pharmaceuticals Inc.
OA Round
1 (Non-Final)
62%
Grant Probability
Moderate
1-2
OA Rounds
93%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allowance Rate
74 granted / 119 resolved
+2.2% vs TC avg
Strong +31% interview lift
Without
With
+31.0%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
38 currently pending
Career history
167
Total Applications
across all art units

Office Action

§102 §103 §112 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims Claims 1-23 are pending. Priority Instant application 18/835,559, filed 08/02/2024 claims priority as follows: PNG media_image1.png 103 664 media_image1.png Greyscale Information Disclosure Statement All references from IDS(s) received 07/21/2025 have been considered unless marked with a strikethrough. Claim Objections Claim 21 is objected to because of the following informalities: the phrase “fat reduction approximately 40%” has a typographical error. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 15-18 and 21 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The term “about” in claims 15-18 is a relative term which renders the claim indefinite. The term “about” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. The specification states at para [0029] that: PNG media_image2.png 166 631 media_image2.png Greyscale The above passage provides multiple definitions for the term “about” which, depending on the definition applied to the claims, result in different claim scope. For example, if “about” means +/- 10%, that results in different claim scope than when “about” means +/- 2%, or when “about” means the specified value. Accordingly, the term “about” in claims 15-18 renders these claims indefinite. The term “approximately” in claim 21 is a relative term which renders the claim indefinite. The term “approximately” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. It is unclear what range of percentages is intended to be covered by the recitation of “approximately 40%”. And because claim 21 has a typographical error (“experiences fat reduction approximately 40%”) it is even more unclear how “approximately” should be interpreted. Does the claim intend to recite fat reduction greater than approximately 40%? Fat reduction less than approximately 40%? Fat reduction equal to approximately 40%? It is unclear and the Specification does not provide guidance because the same typographical error is present there (see, e.g. para. [0062]). Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1-7, 11, 19, 20, and 22-23 are rejected under 35 U.S.C. 102(a)(1) and 35 U.S.C. 102(a)(2) as being anticipated by KHAN (US 20190337903 A1; cited in IDS). Khan discloses a method of reducing adiposity…in a mammal comprising administering to the mammal an effective amount of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole (“Compound 1”) or a pharmaceutically acceptable salt thereof (Khan, claims 1 and 10). With respect to claim 1, Khan’s patient population for “reducing adiposity” is being interpreted as reading on the patient population for “preserving skeletal muscle mass during bodyweight reduction”. The phrase “reducing adiposity” specifically means reducing body fat which is in contrast to reducing body weight (which includes body fat as well as muscle mass, bone mass, and water weight). Therefore, Khan anticipates claim 1 because it discloses administering Compound 1 to the same patient population. With respect to claim 2, Khan’s method specifically recites “reducing adiposity” which is bodyweight reduction attributed to fat reduction. With respect to claims 3 and 4, Khan discloses that Compound 1 is useful for treating obesity or reducing adiposity in a mammal in need thereof ([0097]); and discloses a method of treating obesity or excess body fat comprising administering Compound 1 (claim 5). Khan discloses the treatment of dyslipidemia (claim 6). Khan therefore anticipates claims 3 and 4. With respect to claims 5 and 6, Khan also discloses the treatment of diabetes (claim 3) and type 2 diabetes (T2DM) with Compound 1 (claims 3 and 5). Khan therefore anticipates claims 5 and 6. With respect to claim 7, Khan also discloses the treatment of NAFLD and NASH with Compound 1 (claim 4). Therefore, Khan anticipates claim 7. With respect to claim 11, Khan discloses “controlling or preventing of weight gain” which is being interpreted as reading on “slows the progression of obesity”. Khan therefore anticipates claim 11. With respect to claim 19, Khan discloses administering Compound 1 once daily and discloses administering Compound 1 once daily to diabetic fatty rats (e.g., [0109], [0141], [0149]). Khan therefore anticipates claim 19. Claims 20 and 22-23 recite limitations which are expressions of the intended result of a process step positively recited. As noted in MPEP 2111.04, “a ‘whereby clause in a method claim is not given weight when it simply expresses the intended result of a process step positively recited.’” In the instant case, the results (fat reduction greater than 5%, 10%, 20%, 30%, or 40%; or reduction of lipids, blood pressure, or liver fat) are the biological consequence of administering Compound 1 to the claimed patient population. They do not distinguish from the prior art because the prior art teaches the same active step(s) of administering Compound 1 to the same patient population. Therefore, Khan anticipates claims 20 and 22-23. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1-9, 11, 19, 20, and 22-23 are rejected under 35 U.S.C. 103 as being unpatentable over KHAN (US 20190337903 A1; cited in IDS) in view of AXELROD (The FASEB Journal, vol. 35, no. S1, May 2021). While Khan’s patient population for “reducing adiposity” is being interpreted as reading on the patient population for “preserving skeletal muscle mass during bodyweight reduction”, Khan does not explicitly state that the method preserves muscle mass during bodyweight reduction as recited by the claims. Therefore, should it be found that Khan does not anticipate claims 1-7, 11, 19, 20, and 22-23 as set forth in the rejection under 35 U.S.C. 102 above, the present rejection is also being applied in the alternative to those claims, and additionally includes claims 8-9. The teachings of Khan are disclosed above and at least those teachings are incorporated herein by reference. Khan discloses the mitochondrial uncoupler 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole (hereinafter “Compound 1”) (Khan, abstract, paras. [0005], [0006]); and the use of the compound for treating obesity, diabetes, or insulin resistance or intolerance (claim 3); non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hepatic steatosis, or type 2 diabetes (T2DM) (Khan, claim 4); obesity, or excess body fat (claim 5); dyslipidemia (claim 6); and for reducing adiposity, controlling or preventing of weight gain in a mammal (claim 10). While Khan does not explicitly state that Compound 1 “preserves muscle mass during bodyweight reduction”, it was known in the prior art that mitochondrial uncouplers (a class of compounds that includes Compound 1) were effective for reducing body fat while preserving muscle mass. For example, AXELROD teaches that the mitochondrial uncoupling reverses sarcopenic obesity while enhancing glucose homeostasis and muscle function in aged C57BL/6J mice (Axelrod, title, abstract). In particular, Axelrod teaches that administering the mitochondrial uncoupler BAM15 to 80-week old male C57BL/6J mice resulted in a reduction in body weight by increasing energy expenditure without altering food intake; and that BAM15 reduced body fat while preserving lean mass, increasing muscle strength, and locomotor activity (Axelrod, abstract). As stated in Axelrod, “Taken together, these data indicate that reducing mitochondrial coupling efficiency protects against age-related decline in muscle function while improving peripheral metabolic health” (Axelrod, abstract). Finding of prima facie obviousness The Supreme Court in KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398, 415-421, 82 USPQ2d 1385, 1395-97 (2007) identified a number of rationales to support a conclusion of obviousness which are consistent with the proper "functional approach" to the determination of obviousness as laid down in Graham. See MPEP 2143. Examples of rationales that may support a conclusion of obviousness include: (A) Combining prior art elements according to known methods to yield predictable results; (B) Simple substitution of one known element for another to obtain predictable results; (C) Use of known technique to improve similar devices (methods, or products) in the same way; (D) Applying a known technique to a known device (method, or product) ready for improvement to yield predictable results; (E) "Obvious to try" – choosing from a finite number of identified, predictable solutions, with a reasonable expectation of success; (F) Known work in one field of endeavor may prompt variations of it for use in either the same field or a different one based on design incentives or other market forces if the variations are predictable to one of ordinary skill in the art; (G) Some teaching, suggestion, or motivation in the prior art that would have led one of ordinary skill to modify the prior art reference or to combine prior art reference teachings to arrive at the claimed invention. Applying KSR example rationale (A) and/or (G), it would have been prima facie obvious to administer Compound 1 to preserve skeletal muscle mass during bodyweight reduction in a subject in need thereof, including subjects suffering from obesity, excess body fat, diabetes, high blood pressure, dyslipidemia, hypertriglyceridemia, lipodystrophy, metabolic syndrome, diabetes, T2DM, NAFLD, NASH, sarcopenia, and/or sarcopenic obesity. A skilled artisan would have enjoyed a reasonable expectation of success in view of Khan’s teachings that Compound 1 is a metabolic uncoupler useful for reducing adiposity and treating obesity, diabetes, etc.; and in view of Axelrod’s teachings that mitochondrial uncouplers are useful for reversing sarcopenic obesity while preserving lean muscle mass. Accordingly, claims 1-9, 11, 19, 20, and 22-23 are obvious over Khan in view of Axelrod. Claim 10 is rejected under 35 U.S.C. 103 as being unpatentable over KHAN in view of AXELROD, further in view of CRUZ-JENTOFT (Age and Ageing, vol. 48, no. 1, Jan. 2019, pp. 16–31.). The teachings of Khan in view of Axelrod are disclosed above and at least those teachings are incorporated herein by reference. Khan in view of Axelrod teaches the method of claim 1. With respect to claim 10, Khan in view of Axelrod teaches treating sarcopenia but does not specifically teach that the subject suffers from decreased muscle mass, loss of muscle mass, muscle weakness, decline in muscle strength, slow walking speed, or difficulty performing normal daily activities. However, it was known in the prior art that the criteria recited in claim 10 are diagnostic criteria for sarcopenia. See, for example, Cruz-Jentoft, page 19, Table 2, which lists gait speed, skeletal muscle strength, skeletal muscle mass, and short physical performance battery, as indicators for sarcopenia case finding; and Table 1 which lists low muscle strength, low muscle quantity or quality, and low physical performance as an operational definition of sarcopenia. Applying KSR example rationale (G), it would have been prima facie obvious to administer Compound 1 to preserve skeletal muscle mass during bodyweight reduction in a subject in need thereof, including subjects suffering from sarcopenia or sarcopenic obesity having decreased muscle mass, loss of muscle mass, muscle weakness, etc. A skilled artisan would have enjoyed a reasonable expectation of success in view of Khan’s teachings that Compound 1 is a metabolic uncoupler useful for reducing adiposity and treating obesity; and in view of Axelrod’s teachings that mitochondrial uncouplers are useful for reversing sarcopenic obesity while preserving lean muscle mass. Accordingly, claim 10 is obvious over Khan in view of Axelrod and Cruz-Jentoft. Claims 12-13 and 21 are rejected under 35 U.S.C. 103 as being unpatentable over KHAN in view of AXELROD, further in view of ADA (Diabetes Care, vol. 37, no. Supplement_1, Jan. 2014, pp. S81–90). The teachings of Khan in view of Axelrod are disclosed above and at least those teachings are incorporated herein by reference. Khan in view of Axelrod teaches the method of claim 1. With respect to claims 12-13, Khan teaches treating diabetes but does not specifically disclose that the subject has an abnormal or elevated HbA1c (also known as “A1C”) level. However, it was known in the prior art that an abnormal, elevated A1C level was a diagnostic criterion for diabetes patients. See, for example, ADA, Table 3, titled “Criteria for the diagnosis of diabetes”: PNG media_image3.png 58 520 media_image3.png Greyscale Applying KSR example rationale (G), it would have been prima facie obvious to administer Compound 1 to preserve skeletal muscle mass during bodyweight reduction in a subject in need thereof, including subjects suffering from diabetes having an abnormal or elevated A1C level. A skilled artisan would have enjoyed a reasonable expectation of success in view of Khan’s teachings that Compound 1 is a metabolic uncoupler useful for reducing adiposity and treating obesity and diabetes; and in view of Axelrod’s teachings that mitochondrial uncouplers are useful for reversing sarcopenic obesity while preserving lean muscle mass. Claim 21 recites limitations which are expressions of the intended result of a process step positively recited. As noted in MPEP 2111.04, “a ‘whereby clause in a method claim is not given weight when it simply expresses the intended result of a process step positively recited.’” In the instant case, the results (“fat reduction approximately 40%”) are the biological consequence of administering Compound 1 to the claimed patient population. They do not distinguish from the prior art because the prior art teaches the same active step(s) of administering Compound 1 to the same patient population. Accordingly, claims 12-13 and 21 are obvious over Khan in view of Axelrod and ADA. Claim 14 is rejected under 35 U.S.C. 103 as being unpatentable over KHAN in view of AXELROD, further in view of JIA (US 20190285656 A1). The teachings of Khan in view of Axelrod are disclosed above and at least those teachings are incorporated herein by reference. Khan in view of Axelrod teaches the method of claim 1. With respect to claim 14, Khan teaches treating obesity but does not specifically disclose that the subject has a BMI greater than 28 kg/m2. However, it was known in the prior art that a BMI greater than 28 kg/m2 was a diagnostic criterion for obesity patients. See, for example, JIA, para. [0222], under “Diagnostic Criteria”: PNG media_image4.png 142 509 media_image4.png Greyscale Applying KSR example rationale (G), it would have been prima facie obvious to administer Compound 1 to preserve skeletal muscle mass during bodyweight reduction in a subject in need thereof, including subjects suffering from obesity having BMI greater than 28 kg/m2. A skilled artisan would have enjoyed a reasonable expectation of success in view of Khan’s teachings that Compound 1 is a metabolic uncoupler useful for reducing adiposity and treating obesity; and in view of Axelrod’s teachings that mitochondrial uncouplers are useful for reversing sarcopenic obesity while preserving lean muscle mass. Accordingly, claims 14 is obvious over Khan in view of Axelrod and Jia. Claims 15-18 are rejected under 35 U.S.C. 103 as being unpatentable over KHAN in view of AXELROD, further in view of NAIR (Journal of Basic and Clinical Pharmacy, vol. 7, no. 2, 2016, p. 27). The teachings of Khan in view of Axelrod are disclosed above and at least those teachings are incorporated herein by reference. Khan in view of Axelrod teaches the method of claim 1. With respect to claims 15-18, Khan teaches dosing amounts in units of mg/kg rather than mg. For example, Khan teaches amounts of about 0.01 mg/kg, about 0.1 mg/kg, about 1 mg/kg, about 10 mg/kg, and about 100 mg/kg (Khan, [0117]). Khan and Axelrod do not teach doses in mg as required by the instant claims. However, NAIR is drawn to a guide for dose conversion between species; and provides in Table 1 a reference body weight for various species. In particular, the reference body weight in humans provided by Nair is 60 kg (Nair, Table 1). Applying KSR example rationale (G), it would have been prima facie obvious to convert the doses contemplated by Khan (in mg/kg) into milligrams using adult human reference weight taught by Nair. The doses resulting from the conversion of Nair’s 1 mg/kg and 10 mg/kg include 60 mg and 600 mg, which read on claims 15-18. Moreover, differences in result-effective variables will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating the value of the result-effective variable is critical. See MPEP 2144.05. In the instant case, the dose of Compound 1 is considered a result-effective variable that impacts, for example, the occurrence of undesired side effects in a patient. Absent a showing that the recited doses are critical, optimizing result-effective variables is deemed routine optimization. Accordingly, claims 15-18 are obvious over Khan in view of Axelrod and Nair. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. US 10,618,875 Claims 1-7, 11, 19, 20, and 22-23 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-13 of U.S. Patent No. 10,618,875 (“the reference patent”). Although the claims at issue are not identical, they are not patentably distinct from each other because: The reference patent recites a method of reducing adiposity…in a mammal comprising administering to the mammal an effective amount of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole (“Compound 1”) or a pharmaceutically acceptable salt thereof (Reference patent, claims 1 and 11). With respect to claim 1, the reference patent patient population for “reducing adiposity” is being interpreted as reading on the patient population for “preserving skeletal muscle mass during bodyweight reduction”. The phrase “reducing adiposity” specifically means reducing body fat which is in contrast to reducing body weight (which includes body fat as well as muscle mass, bone mass, and water weight). Therefore, the reference patent anticipates claim 1 because it discloses administering Compound 1 to the same patient population. With respect to claim 2, the reference patent’s method specifically recites “reducing adiposity” which is bodyweight reduction attributed to fat reduction. With respect to claims 3 and 4, the reference patent recites a method for treating obesity or reducing adiposity in a mammal in need thereof (claim 11) and recites a method of treating obesity or excess body fat comprising administering Compound 1 (claim 6). The reference patent also recites the treatment of dyslipidemia (claim 7). With respect to claims 5 and 6, the reference patent also recites the treatment of diabetes (claim 4) and type 2 diabetes (T2DM) with Compound 1 (claims 4 and 5). With respect to claim 7, the reference patent also discloses the treatment of NAFLD and NASH with Compound 1 (claim 5). With respect to claim 11, the reference patent recites “controlling or preventing of weight gain” which is being interpreted as reading on “slows the progression of obesity”. With respect to claim 19, support for the term “effective amount” recited in the claims of the reference patent includes Example 6 (col 24, lines 14-22), which discloses administering Compound 1 once daily to diabetic fatty rats. Claims 20 and 22-23 recite limitations which are expressions of the intended result of a process step positively recited. As noted in MPEP 2111.04, “a ‘whereby clause in a method claim is not given weight when it simply expresses the intended result of a process step positively recited.’” In the instant case, the results (fat reduction greater than 5%, 10%, 20%, 30%, or 40%; or reduction of lipids, blood pressure, or liver fat) are the biological consequence of administering Compound 1 to the claimed patient population. They do not distinguish from the reference patent because the reference patent teaches the same active step(s) of administering Compound 1 to the same patient population. Claims 1-9, 11, 19, 20, and 22-23 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-13 of U.S. Patent No. 10,618,875 in view of AXELROD (The FASEB Journal, vol. 35, no. S1, May 2021). While the reference patent’s patient population for “reducing adiposity” is being interpreted as reading on the patient population for “preserving skeletal muscle mass during bodyweight reduction”, the reference patent does not explicitly state that the method preserves muscle mass during bodyweight reduction as recited by the claims. Therefore, should it be found that the reference patent does not anticipate claims 1-7, 11, 19, 20, and 22-23 as set forth in the rejection under 35 U.S.C. 102 above, the present rejection is also being applied in the alternative to those claims, and additionally includes claims 8-9. The recitations of the reference patent are disclosed above and at least those teachings are incorporated herein by reference. The reference patent recites administering 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole (hereinafter “Compound 1”) to treat obesity, diabetes, or insulin resistance or intolerance (claim 4); non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hepatic steatosis, or type 2 diabetes (T2DM) (Khan, claim 5); obesity, or excess body fat (claim 6); dyslipidemia (claim 7); and for reducing adiposity, controlling or preventing of weight gain in a mammal (claim 11). While the reference patent does not explicitly recite that Compound 1 “preserves muscle mass during bodyweight reduction”, it was known in the prior art that mitochondrial uncouplers (a class of compounds that includes Compound 1) were effective for reducing body fat while preserving muscle mass. For example, AXELROD teaches that the mitochondrial uncoupling reverses sarcopenic obesity while enhancing glucose homeostasis and muscle function in aged C57BL/6J mice (Axelrod, title, abstract). In particular, Axelrod teaches that administering the mitochondrial uncoupler BAM15 to 80-week old male C57BL/6J mice resulted in a reduction in body weight by increasing energy expenditure without altering food intake; and that BAM15 reduced body fat while preserving lean mass, increasing muscle strength, and locomotor activity (Axelrod, abstract). As stated in Axelrod, “Taken together, these data indicate that reducing mitochondrial coupling efficiency protects against age-related decline in muscle function while improving peripheral metabolic health” (Axelrod, abstract). Applying KSR example rationale (A) and/or (G), it would have been prima facie obvious to administer Compound 1 to preserve skeletal muscle mass during bodyweight reduction in a subject in need thereof, including subjects suffering from obesity, excess body fat, diabetes, high blood pressure, dyslipidemia, hypertriglyceridemia, lipodystrophy, metabolic syndrome, diabetes, T2DM, NAFLD, NASH, sarcopenia, and/or sarcopenic obesity. A skilled artisan would have enjoyed a reasonable expectation of success in view of the recitations of the reference patent that Compound 1 is useful for reducing adiposity and treating obesity, diabetes, etc.; and in view of Axelrod’s teachings that mitochondrial uncouplers are useful for reversing sarcopenic obesity while preserving lean muscle mass. Accordingly, claims 1-9, 11, 19, 20, and 22-23 are unpatentable over the reference patent in view of Axelrod. Claim 10 is rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-13 of U.S. Patent No. 10,618,875 in view of AXELROD (The FASEB Journal, vol. 35, no. S1, May 2021), further in view of CRUZ-JENTOFT (Age and Ageing, vol. 48, no. 1, Jan. 2019, pp. 16–31.). The recitations and teachings of the reference patent in view of Axelrod are disclosed above and at least those recitations and teachings are incorporated herein by reference. The reference patent in view of Axelrod teaches the method of claim 1. With respect to claim 10, the reference patent in view of Axelrod teaches treating sarcopenia but does not specifically teach that the subject suffers from decreased muscle mass, loss of muscle mass, muscle weakness, decline in muscle strength, slow walking speed, or difficulty performing normal daily activities. However, it was known in the prior art that the criteria recited in claim 10 are diagnostic criteria for sarcopenia. See, for example, Cruz-Jentoft, page 19, Table 2, which lists gait speed, skeletal muscle strength, skeletal muscle mass, and short physical performance battery, as indicators for sarcopenia case finding; and Table 1 which lists low muscle strength, low muscle quantity or quality, and low physical performance as an operational definition of sarcopenia. Applying KSR example rationale (G), it would have been prima facie obvious to administer Compound 1 to preserve skeletal muscle mass during bodyweight reduction in a subject in need thereof, including subjects suffering from sarcopenia or sarcopenic obesity having decreased muscle mass, loss of muscle mass, muscle weakness, etc. A skilled artisan would have enjoyed a reasonable expectation of success in view of the reference patent’s recitation that Compound 1 is useful for reducing adiposity and treating obesity; and in view of Axelrod’s teachings that mitochondrial uncouplers are useful for reversing sarcopenic obesity while preserving lean muscle mass. 3. Claims 12-13 and 21 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-13 of U.S. Patent No. 10,618,875 in view of AXELROD (The FASEB Journal, vol. 35, no. S1, May 2021), further in view of ADA (Diabetes Care, vol. 37, no. Supplement_1, Jan. 2014, pp. S81–90). The recitations and teachings of the reference patent in view of Axelrod are disclosed above and at least those recitations and teachings are incorporated herein by reference. The reference patent in view of Axelrod teaches the method of claim 1. With respect to claims 12-13, the reference patent in view of Axelrod teaches treating diabetes but does not specifically teach that the subject has an abnormal or elevated HbA1c (also known as “A1C”) level. However, it was known in the prior art that an abnormal, elevated A1C level was a diagnostic criterion for diabetes patients. See, for example, ADA, Table 3, titled “Criteria for the diagnosis of diabetes”: Applying KSR example rationale (G), it would have been prima facie obvious to administer Compound 1 to preserve skeletal muscle mass during bodyweight reduction in a subject in need thereof, including subjects suffering from diabetes having an abnormal or elevated A1C level. A skilled artisan would have enjoyed a reasonable expectation of success in view of the reference patent’s recitation that Compound 1 is a metabolic uncoupler useful for reducing adiposity and treating obesity and diabetes; and in view of Axelrod’s teachings that mitochondrial uncouplers are useful for reversing sarcopenic obesity while preserving lean muscle mass. Claim 21 recites limitations which are expressions of the intended result of a process step positively recited. As noted in MPEP 2111.04, “a ‘whereby clause in a method claim is not given weight when it simply expresses the intended result of a process step positively recited.’” In the instant case, the results (“fat reduction approximately 40%”) are the biological consequence of administering Compound 1 to the claimed patient population. They do not distinguish from the prior art because the prior art teaches the same active step(s) of administering Compound 1 to the same patient population. 4. Claim 14 is rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-13 of U.S. Patent No. 10,618,875 in view of AXELROD (The FASEB Journal, vol. 35, no. S1, May 2021), further in view of JIA (US 20190285656 A1). The recitations and teachings of the reference patent in view of Axelrod are disclosed above and at least those recitations and teachings are incorporated herein by reference. The reference patent in view of Axelrod teaches the method of claim 1. With respect to claim 14, the reference patent in view of Axelrod teaches treating obesity but does not specifically teach that the subject has a BMI greater than 28 kg/m2. However, it was known in the prior art that a BMI greater than 28 kg/m2 was a diagnostic criterion for obesity patients. See, for example, JIA, para. [0222], under “Diagnostic Criteria”: Applying KSR example rationale (G), it would have been prima facie obvious to administer Compound 1 to preserve skeletal muscle mass during bodyweight reduction in a subject in need thereof, including subjects suffering from obesity having BMI greater than 28 kg/m2. A skilled artisan would have enjoyed a reasonable expectation of success in view of the reference patent’s recitation that Compound 1 is a metabolic uncoupler useful for reducing adiposity and treating obesity; and in view of Axelrod’s teachings that mitochondrial uncouplers are useful for reversing sarcopenic obesity while preserving lean muscle mass. 5. Claims 15-18 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-13 of U.S. Patent No. 10,618,875 in view of AXELROD (The FASEB Journal, vol. 35, no. S1, May 2021), further in view of NAIR (Journal of Basic and Clinical Pharmacy, vol. 7, no. 2, 2016, p. 27). The recitations and teachings of the reference patent in view of Axelrod are disclosed above and at least those recitations and teachings are incorporated herein by reference. The reference patent in view of Axelrod teaches the method of claim 1. With respect to claims 15-18, the reference patent in view of Axelrod teaches dosing amounts in units of mg/kg rather than mg. For example, support for the term “effective amount” in the reference patent includes amounts of about 0.01 mg/kg, about 0.1 mg/kg, about 1 mg/kg, about 10 mg/kg, and about 100 mg/kg (Col. 20, lines 1-5). The reference patent and Axelrod do not teach doses in mg as required by the instant claims. However, NAIR is drawn to a guide for dose conversion between species; and provides in Table 1 a reference body weight for various species. In particular, the reference body weight in humans provided by Nair is 60 kg (Nair, Table 1). Applying KSR example rationale (G), it would have been prima facie obvious to convert the doses of the reference patent into milligrams using adult human reference weight taught by Nair. The doses resulting from the conversion of Nair’s 1 mg/kg and 10 mg/kg include 60 mg and 600 mg, which read on claims 15-18. Moreover, differences in result-effective variables will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating the value of the result-effective variable is critical. See MPEP 2144.05. In the instant case, the dose of Compound 1 is considered a result-effective variable that impacts, for example, the occurrence of undesired side effects in a patient. Absent a showing that the recited doses are critical, optimizing result-effective variables is deemed routine optimization. 18/835,578 Claims 1-23 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-8, 10-13, 16, 19-21, 23, 29-30, 32-33, 38, 42-43, and 48 of copending Application No. 18/835,578 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other. Claims of the reference application are directed to a method for weight loss in a subject who has an abnormal HbA1c level, comprising administering Compound 1. The described subject population corresponds to prediabetic and diabetic individuals. The method also describes treatment of obesity and excess body fat. A skilled artisan would have found it obvious to treat the currently claimed disease by administering compound 1 in view of the claims of the reference application. The claims of the reference application also recite clinical endpoints recited by the instant claims, such as reduction of body weight, reduction of lipids, reduction of blood pressure, etc. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. 18/562,560 Claims 1-23 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 8-9, 13-14, 16, 18, 31-35, 130-131, 136, 138-139, 146-147, 156, and 161-163 of copending Application No. 18/562,560 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other. Claims of the reference application are directed to a method for treating heart failure with preserved ejection fraction in a subject, comprising administering Compound 1. The described subject population corresponds to individuals with cardiovascular disease. The method also describes treatment of obesity, excess body fat, diabetes, lipodystrophy, high blood pressure, etc. A skilled artisan would have found it obvious to treat the currently claimed disease by administering compound 1 in view of the claims of the reference application. The claims of the reference application also recite clinical endpoints recited by the instant claims, such as reduction of body weight, reduction of lipids, reduction of blood pressure, etc. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Conclusion Claims 1-23 are rejected. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kyle Nottingham whose telephone number is (571)270-0640. The examiner can normally be reached M-F from 10:00 am - 6:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton Brooks can be reached at (571) 270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /K.N./Examiner, Art Unit 1621 /CLINTON A BROOKS/Supervisory Patent Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Aug 02, 2024
Application Filed
Aug 18, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790324
CRYSTALLINE FORM OF ISAVUCONAZONIUM SULFATE AND A PROCESS FOR ITS PREPARATION
2y 3m to grant Granted Nov 10, 2026
Patent 12778968
TREATMENT FOR FIBROSIS AND INHIBITION OF FIBROSIS
4y 3m to grant Granted Nov 03, 2026
Patent 12760032
HETEROCYCLIC COMPOUNDS
3y 7m to grant Granted Oct 13, 2026
Patent 12747224
FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS
4y 1m to grant Granted Sep 29, 2026
Patent 12747246
FUSED CYCLIC COMPOUND AS WEE-1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF
3y 0m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
62%
Grant Probability
93%
With Interview (+31.0%)
Low
PTA Risk
Based on 119 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month